119 related articles for article (PubMed ID: 35428913)
1. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis.
Krieg S; Roderburg C; Fung S; Luedde T; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2235-2246. PubMed ID: 35428913
[TBL] [Abstract][Full Text] [Related]
2. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract][Full Text] [Related]
4. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Yan Y; Wu D; Wang W; Lv Y; Yang L; Liu Y; Dong P; Yu X
J Cancer Res Ther; 2024 Apr; 20(2):633-641. PubMed ID: 38687934
[TBL] [Abstract][Full Text] [Related]
6. Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis.
Ziogas IA; Tasoudis PT; Borbon LC; Sherman SK; Breheny PJ; Chandrasekharan C; Dillon JS; Bellizzi AM; Howe JR
Ann Surg Oncol; 2023 Jan; 30(1):148-160. PubMed ID: 36227392
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio N; La Salvia A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
[TBL] [Abstract][Full Text] [Related]
8. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.
Fazio N; Gervaso L; Halfdanarson TR; Sonbol M; Eiring RA; Pusceddu S; Prinzi N; Lombardi Stocchetti B; Grozinsky-Glasberg S; Gross DJ; Walter T; Robelin P; Lombard-Bohas C; Frassoni S; Bagnardi V; Antonuzzo L; Sparano C; Massironi S; Gelsomino F; Bongiovanni A; Ranallo N; Tafuto S; Rossi M; Cives M; Rasul Kakil I; Hamid H; Chirco A; Squadroni M; La Salvia A; Hernando J; Hofland J; Koumarianou A; Boselli S; Tamayo D; Mazzon C; Rubino M; Spada F
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36930250
[TBL] [Abstract][Full Text] [Related]
10. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY; Zhao L; Van Hummelen P; Martin B; Hornbacker K; Lee H; Xia LC; Padda SK; Ji HP; Kunz P
Endocr Relat Cancer; 2022 Dec; 29(12):665-679. PubMed ID: 36165930
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of inflammation-related biomarkers in patients with gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Cui LJ; Yu FH; Cheng ZX; Su F; Chen YY; Tan HY
J Neuroendocrinol; 2024 Apr; 36(4):e13381. PubMed ID: 38468159
[TBL] [Abstract][Full Text] [Related]
12. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china.
Fan JH; Zhang YQ; Shi SS; Chen YJ; Yuan XH; Jiang LM; Wang SM; Ma L; He YT; Feng CY; Sun XB; Liu Q; Deloso K; Chi Y; Qiao YL
Oncotarget; 2017 Sep; 8(42):71699-71708. PubMed ID: 29069739
[TBL] [Abstract][Full Text] [Related]
13. "Present and future of immunotherapy in Neuroendocrine Tumors".
Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
[TBL] [Abstract][Full Text] [Related]
14. Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy-A Systematic Review.
Chmiel P; Rychcik-Pazyrska P; Stec R
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958406
[TBL] [Abstract][Full Text] [Related]
15. Disseminated neuroendocrine neoplasm with undetected primary tumor.
Ribeiro FB; Siqueira SAC; Gonçalves MC; Costa ADCL
Autops Case Rep; 2012; 2(3):13-20. PubMed ID: 31528575
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance-A Retrospective, Long-Term Single-Center Experience.
Schmidt M; Hinterleitner C; Singer S; Lauer UM; Zender L; Hinterleitner M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686593
[TBL] [Abstract][Full Text] [Related]
17. Palliative radiotherapy is effective for both well- and poorly differentiated neuroendocrine neoplasms.
O'Reilly E; Lao L; Woodhouse B; Sharples K; Print C; Lawrence B
J Med Imaging Radiat Oncol; 2024 Feb; 68(1):94-102. PubMed ID: 37898955
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study.
Giraldi L; Vecchioni A; Carioli G; Bilotta M; La Rosa S; Imperatori A; Volante M; Brizzi MP; Inzani F; Petrone G; Schinzari G; Bianchi A; Margaritora S; Alfieri S; La Vecchia C; Boccia S; Rindi G
Endocrine; 2021 Jan; 71(1):233-241. PubMed ID: 32869113
[TBL] [Abstract][Full Text] [Related]
19. Not for NEN? Role of External Beam Radiation for Neuroendocrine Neoplasms.
Myrehaug S; Ng S; Hallet J; Singh S
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):785-786. PubMed ID: 37838446
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
